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A B S T R A C T   
Objectives: High prolactin levels have been associated with weight gain and impaired metabolic profiles. While 
treatment with dopamine agonists (DAs) has been shown to improve these parameters, there is a lack of surgical 
series on its comparative effect in prolactinoma patients. 
Methods: In this retrospective, comparative study, consecutive patients with a prolactinoma were enrolled if 
treated with first-line transsphenoidal surgery (TSS) or with DAs. Patients with prolactinomas of Knosp grade >2 
and those with a follow-up <24 months were excluded, as were patients with missing laboratory metabolic 
parameters at baseline and over the long-term. Effects of either treatment on BMI and the metabolic profile were 
analyzed, and independent risk factors for long-term obesity were calculated. 
Results: Primary treatment was TSS for 12 patients (40%) and DAs for 18 patients (60%). At diagnosis, no sig-
nificant differences between the two cohorts were observed with regard to adenoma size, Knosp grading, baseline 
prolactin (PRL) levels, prevalence of hypogonadism, or laboratory metabolic parameters. Mean follow-up was 
51.9 months (range, 24–158). Over the long-term, both TSS and DAs led to the control of hyperprolactinemia 
(92% vs. 72%) and hypogonadism (78% vs. 83%) in the majority of patients. While a significant decrease in 
patients’ BMI and fasting glucose were observed, changes in the lipid profile were marginal and independent of 
the treatment modality. At baseline, increased BMI—but not the primary treatment strategy—was an indepen-
dent predictor of long-term obesity. 
Conclusions: Over the long-term, patients’ BMI and FG improve, but changes in the metabolic profile are marginal 
and independent of the primary treatment. It is presumable that not DAs per se, but rather the control of 
hyperprolactinemia plays a role in patients’ metabolic profile alterations.   
Introduction 
Obesity represents a global epidemic with increased morbidity and 
mortality [1]. Endocrine disorders, in particular Cushing’s syndrome, 
hyperprolactinaemia-induced hypogonadism, acromegaly and hypo-
thyroidism have been associated with weight gain and exacerbated 
metabolic dysfunction [2,3]. The relationship between the metabolic 
syndrome and hyperprolactinemia suggests that prolactin (PRL) may be 
per se a modulator of body weight [4]. Prolactinoma is a frequent source 
of hyperprolactinemia and represents the most common hormone- 
secreting pituitary tumour [5]. While dopamine agonists (DAs) are the 
first-line approach [6–8], transsphenoidal surgery (TSS) has increas-
ingly emerged as an alternative treatment option [9–11]. Reasons 
include the need for ongoing DA therapy in up to four fifths of patients 
and potential adverse medical effects over the long-term [12–16]. 
Improvement of the metabolic profile in prolactinoma patients has 
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been attributed to DA therapy per se [17–19]. Currently, there is a 
paucity of data on the comparative impact of first-line surgery on pro-
lactinoma patients’ body mass index (BMI) and metabolic profile. 
In this cross-sectional long-term follow-up study, we aimed at 
analyzing the effect of either treatment approach in a matched cohort of 
patients, based on their BMI, glucose and lipid profiles. 
Methods 
Study design 
This is a retrospective comparative analysis of a prospectively 
maintained database. We reviewed records from prolactinoma patients 
consecutively treated by either TSS or DAs as first-line therapy between 
January 1997 and December 2015. Clinical and laboratory metabolic 
parameters were assessed at baseline and over the long-term (≥2years). 
All patients fulfilled the diagnostic criteria of having a PRL-secreting 
pituitary adenoma [20]. The Human Research Ethics Committee of 
Bern (Kantonale Ethikkommission KEK Bern, Bern, Switzerland) 
approved the study (KEK n◦ 10-10-2006 and 8-11-2006). 
Inclusion and exclusion criteria 
A flow chart of the patient selection process is depicted in Fig. 1. 
Patients with mixed-secreting adenomas, or those with secondary 
hyperprolactinemia due to antidepressants, opiates or neuroleptics, 
were excluded from the analysis. There were 84 patients treated by TSS 
and 78 patients treated with DAs. Patients with missing metabolic pa-
rameters at baseline and at last follow-up were excluded (n = 73). The 
same was true for patients with a follow-up <24 months (n = 21) or 
those with prolactinomas of a Knosp grade ≥2 (n = 22). The latter was 
done to prevent any selection bias towards medical therapy in pro-
lactinomas infiltrating the cavernous sinus [21]. 
Biochemical assessment 
The following metabolic parameters were measured after an over-
night fast: glucose (i.e., fasting glucose, FG), total cholesterol (TC), low- 
density lipoprotein cholesterol (LDL-C), high-density lipoprotein 
cholesterol (HDL-C), and triglyceride (TG) concentrations. Impaired 
fasting glucose (IFG) was defined as FG values between 6.1 and 6.9 
mmol/l. PRL levels, including the immunoradiometric PRL assay with 
serum dilution in order to overcome the high-dose PRL hook effect 
[22–23], and pituitary axis deficits were assessed. The upper limit of the 
PRL level was 25 µg/L for women and 20 µg/L for men [24]. Impaired 
secretion of one or more pituitary hormones was indicative of hypopi-
tuitarism. Secondary adrenal insufficiency was defined by the presence 
of low serum cortisol levels (<50 nmol/L) or normal cortisol but inad-
equate responses to the adrenocorticotropin (ACTH) stimulation test or 
insulin tolerance test. Secondary hypothyroidism was defined as low- 
normal thyroid-stimulating hormone (TSH) levels and a low free 
thyroxin (FT4) level. A gonadotropin deficiency or central hypogonad-
ism was defined as low-normal levels of gonadotropins in parallel with 
low total estradiol/testosterone levels. Immunohistochemical analysis 
according to the WHO classification for neuroendocrine tumors was 
confirmed in the surgical cohort [25]. 
Assessment of BMI 
Standard BMI was calculated for all patients [26]. A BMI of 21–25 
kg/m2 was considered normal. BMI 26–30 kg/m2 was overweight, and 
BMI > 30 kg/m2) was obese. 
Radiological assessment 
A conventional 1.5-T or 3-Tesla pituitary MRI was conducted at 
diagnosis and at follow-up. The standard protocol included a proton 
density/T2-weighted whole-brain scan with 5 mm slice thickness and 
both unenhanced and contrast-enhanced overlapping 3 mm scans in the 
sagittal and coronal planes over the sellar region, as previously reported 
[21,27]. An adenoma with a diameter of 1–10 mm was defined as a 
microadenoma and an adenoma ≥10 mm as a macroadenoma. Infil-
tration of the cavernous sinus was recorded according to the Knosp 
classification [28–29]. 
Treatment modalities for prolactinomas 
Treatment options were discussed at the weekly interdisciplinary 
pituitary board meeting. Surgery was considered for prolactinomas not 
extending beyond the medial carotid line (i.e., Knosp grade ≤1) [21,30]. 
Fig. 1. Flow chart of patient selection process Out of 162 patients with a prolactinoma, first therapy was TSS in 84 patients and DA in 78 patients. 30 patients met the 
final inclusion criteria. 
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The indication for first-line surgery was further discussed with the pa-
tient. Based on his/her preferences, medical therapy was initiated or 
surgery was performed. Types of DA-agonists, maximal doses, and 
duration of treatment were noted (e.g., bromocriptine, and cabergoline). 
In Switzerland, both treatment options are covered by health insurance, 
so cost should not be a factor in the choice of treatment. In the surgical 
cohort, pituitary surgery was performed using a transseptal, trans-
sphenoidal microsurgical approach (i.e., TSS) with sellar reconstruction 
to prevent cerebrospinal fistula, as previously described [9,10,31–34]. 
Long-term assessment 
If PRL levels had normalized and a tumor reduction of >50% was 
attained at the time of radiological follow-up, DAs were tapered 24 
months after initiation of the medical therapy [35–36]. Recurrence was 
defined as an increase in PRL levels above the normal range (>25 µg/L 
for women, >20 µg/L for men) during the last follow-up period after a 
previous remission, irrespective of radiological findings [37–38]. 
Statistical analysis 
Data were analyzed using IBM SPSS statistical software Version 24.0 
(IBM Corp., New York, NY, USA) and GraphPad Prism (V7.04 software, 
San Diego, CA, USA). Continuous variables were examined for homo-
geneity of variance and are expressed as mean ± SD unless otherwise 
noted. Serum PRL levels are presented as median values and inter-
quartile range (IQR). Categorical variables are given as numbers and 
percentages. For comparisons of means between groups, Student’s t-test 
was used for normally distributed data, and the Mann–Whitney test for 
nonparametric data (i.e., FG, HDL-C, and TG levels). The Wilcoxon 
signed-rank test was used to evaluate paired differences in PRL levels 
before and after treatment. Categorical variables were compared using 
Pearson’s chi-square test or Fisher’s exact test, as appropriate. Odds 
ratios (ORs) and 95% confidence intervals (CIs) of independent factors 
for obesity at last follow-up were analyzed by univariable and multi-
variable logistic regression. The variables tested were: age at diagnosis, 
sex, patient’s BMI (kg/m2), PRL levels at baseline, the primary treatment 
(i.e., DA), hypogonadism, and follow-up time. The multivariable logistic 
regression analysis included all dependent risk factors in the univariable 
regression with a p value ≤ 0.3. Baseline PRL values were log trans-
formed before being imputed in the regression analysis, as data showed 
a positively skewed distribution. Significance level was set at <5%. 
Results 
Baseline characteristics 
Among all patients treated for prolactinomas at our institution in the 
study period, 13 women and 17 men fulfilled the study inclusion 
criteria. Baseline characteristics of patients are detailed in Table 1. First 
therapy was TSS in 12 patients (40%) and DA in 18 (60%). No significant 
differences between the two cohorts were observed with regard to 
prevalence of a macroadenoma, the presence of a Knosp grade 1 ade-
noma, baseline PRL levels, affected pituitary axes including the preva-
lence of hypogonadism, or the metabolic profile (i.e., glucose and lipid 
concentrations). 
Patients with a macroprolactinoma vs. those with a micro-
prolactinoma showed significant differences in their BMI (31.5 ± 4.4 vs. 
26.8 ± 7.5, p = 0.04, Fig. 2A) and HDL-C levels (1.1 ± 0.2 vs. 1.4 ± 0.6; 
p = 0.02), while no significant differences were noted with regard to 
LDL-C (p = 0.35), TC (p = 0.98), TG (p = 0.09), or FG levels (p = 0.24). 
In addition, a significant positive correlation between all patients’ PRL 
and BMI values (r = 0.4, p = 0.03, Fig. 2B) was observed. Likewise, there 
was a significant correlation in all patients between the prevalence of 
hypogonadism and HDL-C levels (r = − 0.48, p = 0.007), as well as TG 
levels (r = 0.52, p = 0.004). 
Characteristics at long-term follow-up 
After a mean follow-up of 51.9 months [24–67], long-term control of 
hyperprolactinemia (92% vs. 72%) and hypogandism (78% vs. 83%) 
was attained in the majority of patients, independent of the primary 
treatment (TSS vs. DAs, respectively). The prevalence of secondary hy-
pothyroidism and secondary adrenal insufficiency was not significantly 
altered compared to baseline, independent of the primary treatment 
strategy (i.e. TSS vs. DAs, see Supplemental Tables 1 and 2). The use of 
gonadotropin replacement therapy was noted in 10 men (59%) and 2 
women (15%) (p = 0.03). With regard to patients’ lipid profiles, no 
significant differences were detected between patients with replacement 
therapy and those without for HCL-C (p = 0.35), LCL-C (p = 0.73), TG (p 
= 0.63), and TC (p = 0.50). This was independent of the gender. 
Long-term changes in patients’ BMI and metabolic parameters are 
detailed in Table 2. In particular, PRL levels decreased significantly over 
the long-term (p = 0.03), independent of the primary treatment; i.e., 
surgery (p = 0.05) or DA therapy (p = 0.01; Fig. 3A). Patients’ BMI 
decreased significantly (p = 0.05), a phenomenon more distinct in the 
surgical (p = 0.02) than in the medical cohort (p = 0.36; Fig. 3B). In the 
long-term, patients with a macroprolactinoma vs. those with a micro-
prolactinoma showed no significant differences in their BMI (29.4 ± 5.1 
vs. 26.5 ± 6.0, p = 0.18; Fig. 2B) While concentrations in FG signifi-
cantly decreased in all patients (p = 0.01), significant improvements in 
the lipid profile were noted for levels of TG (p = 0.02) and TC (p = 0.01), 
but not for HDL-C (p = 0.18), or LDL-C (p = 0.07; Fig. 3C). 
Risk factors for obesity (i.e., BMI ≥ 31 kg/m2) are detailed in Table 3. 
Increased BMI at baseline (OR 1.6, 95% CI 1.1–2.3; p = 0.01), but not 
the primary treatment strategy, was an independent predictor of long- 
term obesity. Baseline PRL levels were significantly higher in patients 
with persisting obesity at last follow-up: 1287 µg/L (IQR 264–38,862 
µg/L) vs. 784 µg/L (IQR 99–4414 µg/L; p = 0.02). 
Table 1 
Patient characteristics at baseline.  
Baseline characteristics All patients DA TSS p 
value 
Number of patients, n 
(%) 
30 (100) 18[60] 12[40]  
Sex (women), n (%) 13[43] 8[44] 5[42] 1 




20[67] 12[67] 8[67] 1 
Knosp grading (Knosp 
grade 1), n (%) 
16[53] 10[56] 6[50] 1 
Affected pituitary axes, 
n (%)     
Gonadotropin 
deficiency, n (%) 




5[17] 2[11] 3[25] 0.64 
Secondary adrenal 
insufficiency, n (%) 
3[10] 1[6] 2[17] 0.55 







BMI (kg/m2) 28.6 ± 6 29.5 ± 6.4 27.7 ± 5.5 0.68 
Triglycerides (mmol/L) 1.6 ± 1.1 1.7 ± 1.3 1.3 ± 0.7 0.69 
Total cholesterol 
(mmol/L) 
5.5 ± 1.2 5.3 ± 1.2 5.5 ± 1.1 0.99 
HDL cholesterol 
(mmol/L) 
1.2 ± 0.4 1.1 ± 0.5 1.3 ± 0.4 0.58 
LDL cholesterol (mmol/ 
L) 
3.6 ± 0.8 3.5 ± 0.9 3.6 ± 0.8 0.82 
Fasting glucose (mmol/ 
L) 
5.4 ± 1.1 5.4 ± 0.3 5.4 ± 1.7 0.17 
Follow-up (months) 51.9 ± 38.1 59.2 ± 38.9 41.0 ± 35.7 0.21 
IQR, interquartile range; n, numbers; BMI, body mass index; SD, standard 
deviation. 
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Metabolic impact of surgery or DAs as first-line treatment 
The impact of TSS or DAs per se on patients’ metabolic profile is 
summarized in the supplementary tables (Tables S1 and S2). Surgery per 
se significantly decreased levels of TG (p = 0.02) and FG (p = 0.04), 
whereas DAs significantly decreased levels of TC (p = 0.05) and FG (p =
0.05). Net changes in patients’ BMI or PRL levels over the long-term 
were not significantly different between the two cohorts (i.e., TSS vs. 
DAs, Table S3). 
With regard to the DA being used, cabergoline was more frequently 
prescribed than bromocriptine. Bromocriptine doses ranged from 2.5 to 
10 mg/day, whereas cabergoline doses ranged from 0.5 to 2 mg/week. 
In the medical cohort, DAs were required in 16 patients (53%) at last 
follow-up, with bromocriptine being noted in 5 (16%) and cabergoline 
in 11 (37%). Thereby, mean (±SD) doses at last follow-up were 3.9 ±
3.4 mg for bromocriptine (daily), and 1.3 ± 1.0 mg for cabergoline 
(weekly). Mean cumulative doses per patient at last follow-up were 971 
mg (range 312–2340 mg) for bromocriptine, and 35 mg (range 3–80 mg) 
for cabergoline. 
In the surgical cohort, cabergoline was required in 5 patients (17%) 
at last follow-up. While none of these patients were taking bromocrip-
tine, mean (±SD) doses for cabergoline (weekly) were 1.1 ± 0.3 mg. 
Mean cumulative doses per patient were 28 mg (range 3–64 mg) for 
cabergoline. 
At last follow-up, 6 patients (20%) were treated with statins: 3 (17%) 
in the medical cohort and 3 (25%) in the surgical cohort (p = 0.66). 
Levels of LDL-C (2.5 ± 1.1 vs. 3.4 ± 1.0; p = 0.07), TC (4.0 ± 1.2 vs. 5.0 
± 1.1; p = 0.09), and TG (1.3 ± 0.5 vs. 1.2 ± 0.4; p = 0.69) were lower in 
the statin cohort, though not significantly. 
Morbidity and mortality 
No mortality has been noted. In the surgical cohort, postoperative 
complications consisted of transient diabetes insipidus in one patient. In 
the medical group, prolonged nausea and vertigo were noted in one 
patient. 
Discussion 
The present analysis significantly adds to the existing literature on 
the comparative effect of first-line surgery and medical therapy on 
prolactinoma patients’ BMI and metabolic profile. Our long-term results 
indicate that i) hyperprolactinemia and associated hypogonadism can be 
controlled in the majority of patients regardless of the primary treat-
ment, ii) normalization of PRL improves patients’ BMI and FG levels, iii) 
marginal changes in patients’ metabolic profiles are noted, and iv) high 
baseline BMI but not the first therapy is a risk for persistent long-term 
obesity. 
Impact on patients’ BMI 
Prolactinoma patients display higher BMI and increased prevalence 
of obesity compared to the general population [17,39]. While we noted a 
significant correlation between BMI and PRL levels, corroborating 
recent results [39], the role of PRL in the pathophysiology of obesity 
remains unclear. Decreases in patients’ BMI levels are not an uncommon 
phenomenon following the control of hyperprolactinaemia [4,40]. DAs 
have been found to reduce body weight, particularly in patients with 
high baseline PRL levels [19,41–42].Interestingly, we noted that 
normalization of PRL improves patients’ BMI, with a significant reduc-
tion in the TSS but not the DA cohort. Although PRL levels in both co-
horts were not significantly different over the long-term, it is presumable 
that not DAs per se, but rather the control of hyperprolactinemia and 
hypogonadism might account for this effect. Namely, the association 
between BMI and PRL levels has recently been strengthened. Increased 
BMI in men with prolactinomas compared to the general population has 
been noted [39]. Similarly, our findings indicate a significantly higher 
BMI in patients with a macroprolactinoma compared to those with a 
microprolactinoma, corroborating previous results [43]. It is conceiv-
able that longer exposure to increased PRL levels, as occurs in men, 
afford for the true effect. Namely, while amenorrhea in women is easily 
detected and investigated, men often do not report the non-specific 
symptoms of hypogonadism, such as loss of libido. Consequently, men 
suffer from hyperprolactinemia and hypogonadism over a much longer 
period, a reason that macroprolactinomas are more commonly seen in 
them [44–45]. Whether hypogonadism and its associated lack of energy 
Fig. 2. Patients’ BMI as a function of their adenoma size and their relation with PRL levels (A) Patients with a macroprolactinoma vs. those with a microprolactinoma 
showed significant differences in their BMI at diagnosis, (31.5 ± 4.4 vs. 26.8 ± 7.5, p = 0.04), but not over the long-term (29.4 ± 5.1 vs. 26.5 ± 6.0, p = 0.18). (B) 
Scatterplot showing a significant positive correlation between all patients’ PRL and BMI values (r = 0.4, p = 0.03). 
Table 2 
Long-term changes in metabolic parameters following treatment of 
hyperprolactinaemia.  
All patients Baseline Long-term FU p value 
Prolactin (μg/L) 856 (154–6473) 11[4–25] 0.01 
Affected pituitary axes, n (%)    
Gonadotropin deficiency, n (%) 23 (77) 6[20] <0.001 
Secondary hypothyroidism, n 
(%) 
5[17] 2[7] 0.42 
Secondary adrenal 
insufficiency, n (%) 
3[10] 4[13] 1 
BMI (kg/m2) 28.6 ± 6 
(19–42.9) 
26.5 ± 6 
(20.2–40) 
0.05 
Triglycerides (mmol/L) 1.6 ± 1.1 1.1 ± 0.4 0.02 
Total cholesterol (mmol/L) 5.5 ± 1.2 4.7 ± 1.2 0.01 
HDL-cholesterol (mmol/L) 1.2 ± 0.4 1.3 ± 0.4 0.18 
LDL-cholesterol (mmol/L) 3.6 ± 0.8 3.4 ± 1.0 0.07 
Fasting glucose (mmol/L) 5.4 ± 1.1 5.2 ± 0.7 0.01 
BMI, body mass index; SD, standard deviation. 
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and physical exercise contributes to the increased BMI in females and 
males remains speculative. Increased BMI could also be related to an 
increase in adenoma-associated hypothalamic pressure rather than the 
effect of hyperprolactinemia itself, but this mechanism might only be 
valid in solid and large adenomas [46–47]. Finally, regardless of how 
hyperprolactinemia influences patients’ BMI [43], control of hyper-
prolactinemia is key in overweight prolactinoma patients. 
Impact on patients’ FG profile 
It has been hypothesized that DAs directly decrease the level of FG in 
obese patients [48–49]. Likewise, Pala et al. described a significant 
reduction in FG levels following treatment with Das [50], in keeping 
with our data showing significantly improved FG levels after DA ther-
apy, but also after TSS. In contrast, Schwetz et al. did not confirm the 
previously described changes in the normalization of the glucose 
metabolism by Das [18]. This is of interest, given the postulated asso-
ciation between high PRL levels and an adverse glucose profile [51–52]. 
Yet, FG may independently improve based on a decrease in PRL levels 
and/or changes in BMI [53]. This corroborates the hypothesis that DAs 
per se alter the glucose metabolism by fortifying the suppression of 
endogenous glucose product, or enhancing the splanchnic glucose up-
take, or through direct hypothalamic alterations [54]. These mecha-
nisms were demonstrated by the use of quick-release bromocriptin in 
obese type 2 diabetic patients [54,55]. The same effect is associated with 
cabergoline therapy [17]. This would not explain why changes were also 
observed in our study cohort following TSS, but it affirms the impor-
tance of controlling hyperprolactinemia over the long-term. 
Impact on patients’ lipid profiles 
The proposed direct effect of DA therapy on the metabolic profile is 
debatable, and might rather be caused by the control of hyper-
prolactinemia and associated hypogonadism over the long-term. 
Namely, we observed that restoration of normoprolactinaemia and 
hypogonadism using either treatment led to a significant decrease in TG 
and TC levels, with no significant changes in LDL-C or HDL-C. Cross- 
sectional studies have shown an association between high PRL levels and 
adverse lipid profile [17,51,53]. Our results are in line with most pub-
lished studies to date which found amelioration of the lipid profile 
following DA therapy, although changes have not been observed in all 
studied lipid parameters. In addition, it has been suggested that TC is 
one of the first metabolic parameters affected by a decrease in PRL levels 
following DA therapy [18]. Namely, levels of TC, but not TG, HDL-C or 
LDL-C, improved at 12 months, with the latter significantly decreasing at 
24 months [56]. In particular, changes in TG and LDL-C levels have been 
attributed to the antilipogenic action in the liver tissue and antilipolytic 
action in adipose tissue afforded by Das [55]. In line with this finding, 
prolactinomas were associated with higher BMI and LDL-C [41]. In 
addition, while gonadotropin replacement didn’t alter patients’ lipid 
profile, it has been shown that low testosterone levels in men might be 
associated with decreased HDL-C and high LDL-C and TG levels [57], but 
this association can be confounded by obesity [58]. While changes in the 
lipid profile following gonadotropin replacement can be marginal or 
nonexistent in men [59], the administration of estrogen in women more 
distinctly decreases LCL-C levels, while increasing HDL-C and TG levels 
[57,60], although we couldn’t confirm this result. 
The reason we did not observe significant improvement in the levels 
of LDL-C or HDL-C following treatment with DAs or gonadotropin 
replacement therapy is unclear, as other studies noted a decrease in LDL- 
C levels with therapy [18]. Reasons may include differences in study 
characteristics, number of patients included, modalities or doses of 
gonadal replacement, as well as the risk of bias in uncontrolled studies. 
Namely, differences in the severity and duration of the diseases and 
intrinsic and extrinsic factors may influence lipid parameters. 
Beside age-specific changes in BMI and metabolic parameters 
Fig. 3. Changes in PRL levels, metabolic parameters and patients’ BMI over the 
long-term (A) PRL levels significantly decreased at long-term follow-up (p =
0.03), independent of the primary treatment strategy; i.e. surgery (p = 0.05) 
and DA therapy (p = 0.01). (B) Over the long-term, a significant reduction in 
levels of TG (p = 0.02), TC (p = 0.01), and FG (p = 0.003), but not HDL-C (p =
0.16) or LDL-C (p = 0.07), was noted. (C) Patients’ BMI significantly decreased 
over the long-term (p = 0.05), and was significant in the surgical (p = 0.02) but 
not the medical (p = 0.34) cohort. 
Table 3 
Risk factors for obesity (i.e., BMI > 30 kg/m2) at last follow-up.  
Risk factors for 











Age 1.0 (0.9–1.1)  0.94   
Sex (women) 1.2 (0.3–6.3)  0.81   
PRL levels at 
diagnosis 
1.8 (0.7–4.7)  0.22 2.3 (0.4–14.8) 0.38 
BMI at diagnosis 1.6 (1.2–2.2)  0.004 1.6 (1.1–2.3) 0.01 
Hypogonadism at 
diagnosis 
3.0 (0.3–30.0)  0.35   
Primary therapy 
(DAs) 
2.0 (0.3–12.5)  0.46 
Follow-up time 1.0 (1.0–1.0)  0.33   
PRL, prolactin; CI, confidence interval; DAs, dopamine agonists. 
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[61,62], glucocorticoids, thyroxine and statin therapy likewise may 
affect the lipid profile [63,64]. Namely, while levels of HDL-C are 
generally increased with glucocorticoids, changes in plasma TG and 
LDL-C vary considerably [65,66]. Secondary hypothyroidism is known 
to increase TC, LDL-C, and TG [67]. In addition, statin therapy lowers 
LDL-C and TC [63]. In the present cohort, the prevalence of pituitary 
axes deficits—apart from hypogonadism—was not high at baseline or 
over the long-term. In addition, 6 patients were undergoing statin 
therapy at last follow-up, and their levels of LDL-C and TC were lower 
compared to the levels of the other subjects, although not significantly. 
Thus, it is conceivable that their effect on the metabolic profile may be 
less strong compared to the long-term control of hyperprolactinemia and 
associated hypogonadism. However, the small sample size of both sub-
jects on statin therapy and those with pituitary axes deficits other than 
secondary hypogonadism may fail to reveal a true association. 
Study strengths and limitations 
The main limitations of our study are its retrospective design, the 
lack of randomization, and the single-center design. Despite the rela-
tively small number of patients included, which may not reveal a true 
association between other factors influencing the metabolic profile (i.e., 
hormonal deficits, statin therapy), a strong point of our study is the 
collection of data over 20 years, as well as its homogeneity in terms of 
indications, treatment and follow-up. However, given the long-term 
follow-up, and there have been advances in the medical treatment and 
patients’ surveillance over time, which may confound outcomes. In 
addition, GH may vary the metabolic parameters, but was not system-
atically measured in this study. 
Conclusion 
Over the long-term, patients’ BMI and FG improve. However, 
changes in the metabolic profile are marginal and independent of the 
primary treatment. It is possible that it is not DAs per se, but rather the 
management of hyperprolactinemia and hypogonadism that plays a role 
in patients’ metabolic profile alterations. Considering the clinical sig-
nificance of obesity and impaired metabolic profile in prolactinoma 
patients, our results underline the importance of long-term control of 
hyperprolactinemia. 
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